Answers are grounded in this paper and cite their sources.
The results of this trial suggest that bortezomib has an antitumor effect in individual patients with metastatic RCC. The small proportion of patients who achieved a partial response does not support routine use in metastatic RCC. Efforts to identify the molecular profile associated with clinical response or combination therapy with interferon alfa or other novel agents, may be considered.
No takes yet. Share an insight, caveat, or question.
Kondagunta et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: